Fertin Pharma is very excited about the recent launch of our new Enterprise Resource Planning (ERP) system, which is based on the latest SAP 4/Hana platform. The new system, with more than 1,400 different SAP tiles, supports our long-term growth strategy and strong commitment to customers and partners. It enables us to increase our responsiveness
Peter Halling has been appointed CEO of Fertin Pharma and will join in August 2020. Peter brings extensive experience from working in international environments of production companies in complex and contract-driven markets. He most recently served as an Executive Vice President at Döhler Group but prior to that held various roles at Ingredion and Novozymes.
Succeeds Tom Hoeltgen, who is set to retire in December, 2020 Fertin Pharma, a leading contract development and manufacturing organization (CDMO), has appointed John Stephen as CEO of Tab Labs, its Vancouver-based subsidiary. Stephen has been active in the dietary and supplement field for over 30 years. Fertin, which has four decades of experience and
U.S. Patent No. 10,632,076 B2 further strengthens Fertin Pharma’s intellectual property (IP) portfolio Vejle, Denmark, April 28, 2020 – Fertin Pharma, a contract development and manufacturing organization (CDMO) with more than 40 years of experience, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,632,076 B2. The patent
On 11 March, 2020, the Danish Prime Minister declared a shut-down of parts of the public sector in Denmark due to the development of Covid-19. This means that in-door assemblies with more than 100 attendees are no longer allowed and universities, schools, etc. will be closed for the next two weeks. At Fertin Pharma we